Since 2002, Peter has been involved in the creation of several novel therapeutic and drug discovery platform companies at Atlas. He is also an Executive Fellow at Harvard Business School, where he is the faculty chair of the key advisory board of the Blavatnik Fellowship Program.

Peter is currently chairman of Synlogic (NASDAQ:SYBX), and also serves on the board Obsidian Therapeutics. He previously served on the boards of past Atlas companies Cadent Therapeutics (acquired by Novartis), Larimar Therapeutics (NASDAQ:LRMR), Vitae Pharmaceuticals (NASDAQ:VTAE; acquired by Allergan), Stromedix (acquired by Biogen), Novamed (acquired by Sciclone), Alnylam (NASDAQ:ALNY), Harbour Antibodies (acquired by Harbour Biomed), Momenta (NASDAQ:MNTA), Sirion Therapeutics (acquired by Alcon and Bausch & Lomb), Archemix (acquired by Baxter) and a number of other ventures.

Prior to joining Atlas Peter was co-founder, executive vice president, and chief business officer of Celera Genomics, which announced the first successful sequencing of the human genome in 2001. While at Celera, Peter led strategic alliances, acquisitions, and business strategy and helped launch it as a public company in 1999.

Prior to founding Celera, Peter held senior management positions at Applera, most recently serving as vice president of corporate planning and business development. During his tenure, he ran several businesses and expanded the life science business through a series of licensing agreements, partnerships, and acquisitions.

Peter also serves on the board of Revvity (NYSE:RVTY).

Peter received a BS in chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell), and a PhD in analytical chemistry from Northeastern University. He also completed Harvard Business School’s Management Development Program.

Outside the office, Peter enjoys skiing, competitive sailing, and the theater. Peter and his wife Mary live in Boston. They have three children, three granddaughters, and two grandsons.